Specific changes relating to tumor activation that may serve as potential biomarkers for staging, and prognostication include activated integrin α2b-β3, lysosomal-activated membrane protein (CD63), P-selectin (CD62P), and CD24 that may be detected by flow cytometry together with platelet-specific antigens such as the glycoprotein complexes Ib-IX-V, GPIIb, and GPIIIa [37]. The gene discussed is SELP; the disease is neoplasm.